• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Aspira Women's Health Inc.

    2/13/25 7:01:44 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AWH alert in real time by email
    RW 1 formrw.htm

     

    ASPIRA WOMEN’S HEALTH INC.

    12117 Bee Caves Road, Building III, Suite 100

    Austin, Texas 78738

     

    February 13, 2025

     

    Securities and Exchange Commission

    Division of Corporation Finance

    100 F Street, NE

    Washington, D.C. 20549

     

     

      Re: Aspira Women’s Health Inc.
        File No. 333-284182
        Application for Withdrawal on Form RW pursuant to Rule 477 of the
        Securities Act of 1933 of the Registration Statement on Form S-1

     

    Ladies and Gentlemen:

     

    Pursuant to Rule 477 (“Rule 477”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Aspira Women’s Health Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-284182) as filed with the Commission on February 11, 2025, together with all exhibits thereto (the “Registration Statement”).

     

    The Registrant is requesting the withdrawal of the Registration Statement because the Registrant has decided not to pursue a public offering of its securities at this time due to the availability of other opportunities that the Board of Directors of the Company deemed to be in the best interests of the Company and its stockholders. The Registration Statement was not declared effective by the Commission and none of the Registrant’s securities were sold pursuant to the Registration Statement. The Registrant believes that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477.

     

    The Registrant acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Registrant requests, in accordance with Rule 457(p) under the Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Registrant’s account to be offset against the filing fee for any future registration statement or registration statements of the Registrant or an affiliate.

     

    It is our understanding that this application for withdrawal of the Registration Statement will be deemed granted as of the date that it is filed with the Commission unless, within fifteen days after such date, the Registrant receives notice from the Commission that this application will not be granted.

     

    If you have any questions regarding the foregoing application for withdrawal, please contact the Company’s counsel, Jeffrey Fessler, Esq. of Sheppard Mullin Richter & Hampton, LLP, at (212) 634-3067.

     

      Sincerely,
       
      Aspira Women’s Health Inc.
       
      By: /s/ Michael Buhle
        Michael Buhle
        Chief Executive Officer and Chief Commercial Officer

     

    -1-

    Get the next $AWH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AWH

    DatePrice TargetRatingAnalyst
    1/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fraser John D claimed ownership of 841,558 shares (SEC Form 3)

    3 - Aspira Women's Health Inc. (0000926617) (Issuer)

    4/28/25 7:19:40 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Hundorfean Cynthia D

    3 - Aspira Women's Health Inc. (0000926617) (Issuer)

    4/24/25 9:41:23 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Vos Ellen O'Connor converted options into 5,313 shares, increasing direct ownership by 8% to 68,677 units (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    4/2/25 8:23:47 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

    Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

    1/10/25 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    12/16/24 8:45:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

    AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

    12/3/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on Aspira Women's Health with a new price target

    Cantor Fitzgerald resumed coverage of Aspira Women's Health with a rating of Overweight and set a new price target of $4.00

    1/12/22 7:53:25 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Truist Securities initiated coverage on Aspira Womens Health with a new price target

    Truist Securities initiated coverage of Aspira Womens Health with a rating of Buy and set a new price target of $12.00

    3/29/21 7:32:28 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cantor Fitzgerald initiated coverage on Aspira Womens Health with a new price target

    Cantor Fitzgerald initiated coverage of Aspira Womens Health with a rating of Overweight and set a new price target of $10.00

    1/29/21 6:12:39 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Aspira Women's Health Inc.

    S-1/A - Aspira Women's Health Inc. (0000926617) (Filer)

    4/30/25 8:10:19 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEFR14A filed by Aspira Women's Health Inc.

    DEFR14A - Aspira Women's Health Inc. (0000926617) (Filer)

    4/22/25 4:05:41 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Aspira Women's Health Inc. (0000926617) (Filer)

    4/16/25 5:07:30 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Schuler Jack W bought 6,536 shares (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    7/11/24 5:15:45 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Large owner Schuler Jack W bought 28,500 shares (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    6/18/24 4:12:21 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Sandford Nicole bought $22,973 worth of shares (9,493 units at $2.42), increasing direct ownership by 16% to 70,596 units (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    6/3/24 5:30:57 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Leadership Updates

    Live Leadership Updates

    View All

    Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    12/16/24 8:45:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

    AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

    9/5/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

    AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

    7/29/24 9:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Financials

    Live finance-specific insights

    View All

    Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

    Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

    11/14/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

    AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

    11/4/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

    AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

    7/31/24 4:05:00 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aspira Women's Health Inc.

    SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)

    11/14/24 3:23:57 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

    SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

    7/11/24 5:14:26 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

    SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

    6/18/24 4:13:01 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care